| Micro-channel |
 |
|
|
|
|
|
| |
| Chinese pharmaceutical companies research and develop, these 50 strongest! |
| |
| Author：中國(guó)銘鉉 企劃部 Release Time：2017-9-18 11:00:50 Number Browse：1008 |
| |
Medical network - on September 18, recently, jointly organized by drug intelligence network, China pharmacy magazine of 2017 Chinese medicine theory of innovation summit held in chongqing, solemnly announced at the meeting the list of "2017 Chinese medicine research and development strength, let's take a look at this list:
2017 China pharmaceutical enterprise r&d strength list
|
排名
|
公司名稱
|
|
1
|
正大天晴藥業(yè)集團(tuán)股份有限公司
|
|
2
|
齊魯制藥有限公司
|
|
3
|
江蘇恒瑞醫(yī)藥股份有限公司
|
|
4
|
上海復(fù)星醫(yī)藥（集團(tuán)）股份有限公司
|
|
5
|
浙江海正藥業(yè)股份有限公司
|
|
6
|
江蘇豪森藥業(yè)集團(tuán)有限公司
|
|
7
|
東陽(yáng)光藥業(yè)
|
|
8
|
四川科倫藥業(yè)股份有限公司
|
|
9
|
山東羅欣藥業(yè)集團(tuán)股份有限公司
|
|
10
|
揚(yáng)子江藥業(yè)集團(tuán)有限公司
|
|
11
|
南京華威醫(yī)藥科技集團(tuán)有限公司
|
|
12
|
石藥集團(tuán)有限公司
|
|
13
|
上海醫(yī)藥集團(tuán)股份有限公司
|
|
14
|
浙江華海藥業(yè)股份有限公司
|
|
15
|
四環(huán)醫(yī)藥控股集團(tuán)有限公司
|
|
16
|
江蘇奧賽康藥業(yè)股份有限公司
|
|
17
|
瑞陽(yáng)制藥有限公司
|
|
18
|
麗珠醫(yī)藥集團(tuán)股份有限公司
|
|
19
|
人福醫(yī)藥集團(tuán)股份公司
|
|
20
|
中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所
|
|
21
|
天士力制藥集團(tuán)股份有限公司
|
|
22
|
健康元藥業(yè)集團(tuán)股份有限公司
|
|
23
|
江蘇康緣藥業(yè)股份有限公司
|
|
24
|
山東步長(zhǎng)制藥股份有限公司
|
|
25
|
海思科醫(yī)藥集團(tuán)股份有限公司
|
|
26
|
天津市醫(yī)藥集團(tuán)有限公司
|
|
27
|
云南沃森生物技術(shù)股份有限公司
|
|
28
|
中國(guó)人民解放軍軍事醫(yī)學(xué)科學(xué)院毒物藥物研究所
|
|
29
|
江西施美藥業(yè)股份有限公司
|
|
30
|
南京海納醫(yī)藥科技股份有限公司
|
|
31
|
青峰醫(yī)藥集團(tuán)有限公司
|
|
32
|
辰欣藥業(yè)股份有限公司
|
|
33
|
百濟(jì)神州
|
|
34
|
先聲藥業(yè)有限公司
|
|
35
|
哈爾濱譽(yù)衡藥業(yè)股份有限公司
|
|
36
|
中國(guó)科學(xué)院上海藥物研究所
|
|
37
|
成都苑東生物制藥股份有限公司
|
|
38
|
天津市漢康醫(yī)藥生物技術(shù)有限公司
|
|
39
|
濟(jì)南百諾醫(yī)藥科技開(kāi)發(fā)有限公司
|
|
40
|
上海現(xiàn)代制藥股份有限公司
|
|
41
|
華邦生命健康股份有限公司
|
|
42
|
魯南制藥集團(tuán)股份有限公司
|
|
43
|
四川百利藥業(yè)有限責(zé)任公司
|
|
44
|
深圳信立泰藥業(yè)股份有限公司
|
|
45
|
信達(dá)生物制藥（蘇州）有限公司
|
|
46
|
石家莊以嶺藥業(yè)股份有限公司
|
|
47
|
浙江醫(yī)藥股份有限公司
|
|
48
|
貝達(dá)藥業(yè)股份有限公司
|
|
49
|
華東醫(yī)藥股份有限公司
|
|
50
|
北京康立生醫(yī)藥技術(shù)開(kāi)發(fā)有限公司
|
In addition to this list, there are "top 50" list of "2017 Chinese medicine r&d strength", which includes pharmaceutical companies' key concerns.
It is pointed out that chemical medicine has been the core of the research and development of pharmaceutical companies in China, and the research and development degree is much higher than that of traditional Chinese medicine and biological medicine, so this is also the field of pharmaceutical enterprises. According to drug intelligence data statistics, in 2000-2017 (as of September 1) accept the medicine a total of 118763, accounting for 71.84% of the total acceptance number, including medicine new medicine 36415, accounted for 30.66%, thus it can be seen that the medicine has been the highlight of pharmaceutical research, prospects.
Since our entry into the wto, innovative drugs have sprung up frequently. But there are few new drugs in the country that are truly internationally recognized. Most are generic drugs, and fewer are independently developed.
Some people in the industry say that more than 80% of the sales of foreign drugs can return to production enterprises, providing adequate financial support for further research and development. Some large multinational pharmaceutical companies spend between 10% and 20% of their profits on research and development. In our country, only a small percentage of product sales can return to the production enterprise, some only 10% ~ 20%.
In the past, many drug companies focused on marketing rather than research and development. Faced with huge cost of new drug research and development, combined with the new drug research and development cycle is long, high risk, many drug companies no desire to get new drug research and development, but more in marketing, in order to beat the competition in the market, thus neglected the development process.
In recent years, relevant departments of the state are encouraging the innovation and development of drug companies in new drugs, which undoubtedly gives the domestic pharmaceutical companies an opportunity to develop new drugs. Therefore, many pharmaceutical companies have gradually changed the concept of "resale and light development", and began to pay more attention to the development of enterprises, thus promoting the development of the whole pharmaceutical industry.
Under the efforts of major drug companies over the past year, with the release of "top 50 of China's r&d strength of 2017", the list of the most powerful pharmaceutical companies in 2017 has been settled and the list of drug companies listed on the list is well deserved.
Here are the top 50 pharmaceutical companies listed in China in 2017.
Top 50 of China's pharmaceutical r&d strength in 2017
|
| |
Previous article：The "flying inspection" + centralized control of 93 pharmaceutical companies in the six provinces were examined
Next article：Chinese pharmaceutical companies research and develop, these 50 strongest!
|
| |
|
|
